STI Stock Trade Intelligence
OIL

OPTISCAN IMAGING LIMITED

Health Care · ASX:OIL
$0.1600
▼ -3.03%
Market cap
$167M
Turnover
$172,271
Last price
$0.1600
Day change
-3.03%
Announcements
15
Range, past year
Open 0.135 · Low 0.078 · Now 0.160 · High 0.200
Open OIL in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

OIL momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-10-13.
Momentum quality
37/100
Wyckoff phase
Accumulation1d
Trend stage
Emerging
1 Day
-3.0%
1 Week
-11.1%
1 Month
+0.0%
1 Year
+28.0%
RSI
52
Avg daily range
9.9%

OPTISCAN IMAGING LIMITED scores 37 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Emerging.

On the Wyckoff cycle it sits in Accumulation, where it has been for 1 trading day. The weekly timeframe reads Uptrend, which does not yet agree with the daily view.

Against the wider market it is currently outperforming and the institutional accumulation signal reads low.

Points to watch
  • 60d drawdown -33.3%
  • High volatility (ATR 9.9%)
  • Risk rating: High
  • Composite downside risk elevated
OIL appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

OIL announcements

Recent price-sensitive releases.
  • 2026-10-05 Optiscan Lodges U.S. FDA 510(k) Submission for InVue Progress Report
  • 2026-10-01 Optiscan Lodges U.S. FDA 510(k) Submission for InForm Progress Report
  • 2026-09-10 Significant Milestone Reached in ACL Digital Pathology Study Progress Report
  • 2026-09-01 Optiscan Initiates Head and Neck Cancer Study in the US Progress Report
  • 2026-08-25 Preliminary Final Report Preliminary Final Report
  • 2026-07-31 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
  • 2026-07-22 Optiscan Signs New Research Agreement for Breast Study
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.